Homology Medicines, Inc. (0T6G.L)
USD 1.57
(-3.38%)
USD 1.57
(-3.38%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 18.43 Million USD | 659.39% |
| 2022 | -4.5 Million USD | 94.66% |
| 2021 | -84.44 Million USD | 58.19% |
| 2020 | -201.98 Million USD | -275.63% |
| 2019 | -53.77 Million USD | -40.7% |
| 2018 | -38.22 Million USD | 25.89% |
| 2017 | -51.57 Million USD | -352.72% |
| 2016 | -11.39 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -81.41 Million USD | 22.28% |
| 2024 Q1 | -95.36 Million USD | -151.3% |
| 2023 Q1 | -10.35 Million USD | -129.61% |
| 2023 Q3 | -773 Thousand USD | 98.39% |
| 2023 FY | -37.94 Million USD | -741.61% |
| 2023 Q4 | -37.94 Million USD | -4809.18% |
| 2023 Q2 | -48.07 Million USD | -364.34% |
| 2022 Q3 | -13.33 Million USD | 91.24% |
| 2022 Q2 | -152.19 Million USD | 32.1% |
| 2022 Q1 | -224.14 Million USD | -165.42% |
| 2022 Q4 | -4.5 Million USD | 66.19% |
| 2022 FY | -4.5 Million USD | 94.66% |
| 2021 Q3 | -82.28 Million USD | 19.42% |
| 2021 Q4 | -84.44 Million USD | -2.62% |
| 2021 FY | -84.44 Million USD | 58.19% |
| 2021 Q2 | -102.12 Million USD | -13.98% |
| 2021 Q1 | -89.59 Million USD | 58.79% |
| 2020 FY | -201.98 Million USD | -275.63% |
| 2020 Q3 | -178 Million USD | -6.18% |
| 2020 Q4 | -217.43 Million USD | -22.15% |
| 2020 Q2 | -167.63 Million USD | -16.92% |
| 2020 Q1 | -143.37 Million USD | -166.62% |
| 2019 Q2 | -115.56 Million USD | -182.98% |
| 2019 FY | -53.77 Million USD | -40.7% |
| 2019 Q1 | -40.83 Million USD | -6.85% |
| 2019 Q4 | -53.77 Million USD | 30.67% |
| 2019 Q3 | -77.55 Million USD | 32.89% |
| 2018 Q2 | -94.96 Million USD | -105.48% |
| 2018 FY | -38.22 Million USD | 25.89% |
| 2018 Q4 | -38.22 Million USD | -6.05% |
| 2018 Q3 | -36.03 Million USD | 62.05% |
| 2018 Q1 | -46.21 Million USD | 10.4% |
| 2017 FY | -51.57 Million USD | -352.72% |
| 2017 Q1 | 11.39 Million USD | 0.0% |
| 2017 Q4 | -51.57 Million USD | 0.0% |
| 2016 FY | -11.39 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | 117.909% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 159.061% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 90.691% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 42.177% |
| bluebird bio, Inc. | 108.57 Million USD | 83.018% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 304.492% |
| Imunon, Inc. | -4.69 Million USD | 492.337% |
| Editas Medicine, Inc. | -87.11 Million USD | 121.164% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 99.857% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 99.121% |
| Myriad Genetics, Inc. | 88.1 Million USD | 79.073% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 89.601% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 154.991% |
| Verastem, Inc. | -37.27 Million USD | 149.458% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 99.776% |
| Waters Corporation | 1.96 Billion USD | 99.06% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 99.931% |
| Biogen Inc. | 6.28 Billion USD | 99.707% |
| Nektar Therapeutics | 210.24 Million USD | 91.23% |
| Perrigo Company plc | 3.32 Billion USD | 99.445% |
| Dynavax Technologies Corporation | 106.63 Million USD | 82.71% |
| Illumina, Inc. | 1.21 Billion USD | 98.481% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -164.592% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 116.189% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 87.291% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -156.533% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 95.132% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 359.676% |
| Evolus, Inc. | 63.7 Million USD | 71.06% |
| Adicet Bio, Inc. | -142 Million USD | 112.983% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 150.095% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 168.033% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 95.981% |
| FibroGen, Inc. | 56.76 Million USD | 67.522% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 98.39% |
| OPKO Health, Inc. | 230.68 Million USD | 92.008% |
| Geron Corporation | 14.76 Million USD | -24.903% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 98.837% |
| Exelixis, Inc. | -73.05 Million USD | 125.239% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 133.981% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 112.208% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 116.55% |
| Zoetis Inc. | 4.76 Billion USD | 99.613% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 109.227% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 283.07% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 100.193% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 226.523% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 98.251% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 98.096% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 113.617% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 98.665% |
| Blueprint Medicines Corporation | 702.83 Million USD | 97.377% |
| Insmed Incorporated | 721.62 Million USD | 97.445% |
| TG Therapeutics, Inc. | 17.86 Million USD | -3.219% |
| Incyte Corporation | -3.17 Billion USD | 100.581% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 97.592% |